Molecular Partners (NASDAQ:MOLN) vs. enGene (NASDAQ:ENGN) Head to Head Contrast

enGene (NASDAQ:ENGN) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Profitability

This table compares enGene and Molecular Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-16.69%	-14.27%
Molecular Partners	-1,043.01%	-39.31%	-35.46%

Valuation and Earnings

This table compares enGene and Molecular Partners”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$55.14 million	($0.58)	-10.52
Molecular Partners	$6.00 million	32.82	-$69.04 million	($2.15)	-2.27

enGene has higher earnings, but lower revenue than Molecular Partners. enGene is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for enGene and Molecular Partners, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	1	8	1	3.00
Molecular Partners	0	0	0	1	4.00

enGene currently has a consensus price target of $25.89, suggesting a potential upside of 324.41%. Given enGene’s higher probable upside, analysts plainly believe enGene is more favorable than Molecular Partners.

Volatility & Risk

enGene has a beta of -0.65, indicating that its share price is 165% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Institutional & Insider Ownership

64.2% of enGene shares are owned by institutional investors. Comparatively, 26.5% of Molecular Partners shares are owned by institutional investors. 13.7% of enGene shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

enGene beats Molecular Partners on 9 of the 13 factors compared between the two stocks.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.